Gene therapy is a potential therapeutic strategy for treating hereditary movement disorders, including hereditary ataxia, dystonia, Huntington’s disease, and Parkinson’s disease. Genome editing is a type of genetic engineering in which DNA is inserted, deleted or replaced in the genome using modified nucleases. Recently, clustered regularly interspaced short palindromic repeat/CRISPR associated protein 9 (CRISPR/Cas9) has been used as an essential tool in biotechnology. Cas9 is an RNA-guided DNA endonuclease enzyme that was originally associated with the adaptive immune system of Streptococcus pyogenes and is now being utilized as a genome editing tool to induce double strand breaks in DNA. CRISPR/Cas9 has advantages in terms of clinical applicability over other genome editing technologies such as zinc-finger nucleases and transcription activator-like effector nucleases because of easy in vivo delivery. Here, we review and discuss the applicability of CRISPR/Cas9 to preclinical studies or gene therapy in hereditary movement disorders.
Citations
Citations to this article as recorded by
Effects of Electroporation Timing and Cumulus Cell Attachment on In Vitro Development and Genome Editing of Porcine Embryos Nanaka Torigoe, Qingyi Lin, Bin Liu, Yuichiro Nakayama, Aya Nakai, Megumi Nagahara, Fuminori Tanihara, Maki Hirata, Takeshige Otoi Reproduction in Domestic Animals.2025;[Epub] CrossRef
Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson’s Disease Young Cha, Tae-Yoon Park, Pierre Leblanc, Kwang-Soo Kim Journal of Movement Disorders.2023; 16(1): 22. CrossRef
Crispr-a novel approach towards a fortified immune system Vasudevan Ranganathan, Padma Madham, Prerana Shankpal, Charitha Sheri Journal of Microbiology & Experimentation.2023; 11(3): 73. CrossRef
Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases Della Grace Thomas Parambi, Khalid Saad Alharbi, Rajesh Kumar, Seetha Harilal, Gaber El-Saber Batiha, Natália Cruz-Martins, Omnia Magdy, Arafa Musa, Dibya Sundar Panda, Bijo Mathew Molecular Neurobiology.2022; 59(1): 191. CrossRef
Effects of the timing of electroporation during in vitro maturation on triple gene editing in porcine embryos using CRISPR/Cas9 system Zhao Namula, Manita Wittayarat, Lanh Thi Kim Do, Thanh Van Nguyen, Qingyi Lin, Koki Takebayashi, Maki Hirata, Fuminori Tanihara, Takeshige Otoi Veterinary and Animal Science.2022; 16: 100241. CrossRef
Will CRISPR-Cas9 Have Cards to Play Against Cancer? An Update on its Applications Precilla S. Daisy, Kuduvalli S. Shreyas, T. S. Anitha Molecular Biotechnology.2021; 63(2): 93. CrossRef
The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing Parichehr Hassanzadeh Life Sciences.2021; 274: 119289. CrossRef
CRISPR/Cas9 Technology as a Modern Genetic Manipulation Tool for Recapitulating of Neurodegenerative Disorders in Large Animal Models Mahdi Barazesh, Shiva Mohammadi, Yadollah Bahrami, Pooneh Mokarram, Mohammad Hossein Morowvat, Massoud Saidijam, Morteza Karimipoor, Soudabeh Kavousipour, Amir Reza Vosoughi, Korosh Khanaki Current Gene Therapy.2021; 21(2): 130. CrossRef
La edición del ADN Ithzayana Madariaga-Perpiñan, Juan Camilo Duque-Restrepo, Paola Ayala-Ramirez, Reggie García-Robles Iatreia.2020; 33(3): 262. CrossRef
Mucuna pruriens in Parkinson’s and in some other diseases: recent advancement and future prospective Sachchida Nand Rai, Vivek K. Chaturvedi, Payal Singh, Brijesh Kumar Singh, M. P. Singh 3 Biotech.2020;[Epub] CrossRef
Current Approaches to the Treatment of Hunter Syndrome Ekaterina Yu. Zakharova, Elena Yu. Voskoboeva, Alla N. Semyachkina, Nato D. Vashakmadze, Amina I. Gamzatova, Svetlana V. Mikhailova, Sergey I. Kutsev Pediatric pharmacology.2018; 15(4): 324. CrossRef